Selective BuChE Inhibitor for Alzheimer's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly in severe stages, lack effective drugs that can safely and specifically target butyrylcholinesterase (BuChE), leading to inadequate symptom relief and significant side effects.
Innovation Solution
Development of a selective BuChE inhibitor with a new chemical backbone, designed to have high biological activity, safety, and bioavailability, which selectively inhibits BuChE to restore acetylcholine levels in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective BuChE inhibitors are used to treat severe Alzheimer's disease, then therapeutic efficacy is improved, but peripheral cholinergic side effects occur due to lack of tissue selectivity
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific structural features (aromatic rings, hydrogen bond donors/acceptors, hydrophobic regions) that enable selective interaction with the BuChE active site. The compound structure is optimized to fit the BuChE binding pocket while avoiding AChE, achieving tissue-selective inhibition that improves therapeutic efficacy without causing peripheral side effects
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters including the types of aromatic rings (pyridine, pyrimidine, triazine), substitution patterns, and hydrogen bonding capabilities. These parameter optimizations enable the inhibitor to achieve high selectivity for BuChE over AChE, resolving the contradiction between efficacy and side effects
2Reliability
If existing ChEI drugs are used for Alzheimer's treatment, then mild symptoms are alleviated, but severe AD lacks effective treatment options
Solution Approach 1:
The patent applies dynamics by designing a flexible molecular structure that can adapt to different BuChE conformations and binding modes. The inhibitor contains rotatable bonds and adaptable functional groups that allow it to effectively bind to BuChE in various disease stages, providing consistent therapeutic effect from mild to severe Alzheimer's disease
Solution Approach 2:
The patent uses composite materials by combining multiple functional moieties within a single inhibitor molecule: aromatic rings for hydrophobic interaction, hydrogen bond donors and acceptors for specific binding, and appropriate substituents for optimal pharmacokinetics. This composite structure enables the drug to effectively treat severe AD while maintaining safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selective BuChE inhibitor demonstrates excellent target activity in vitro, offering high selectivity and safety, making it a promising lead for further development in treating Alzheimer's disease.
Implementation Method 1
selective butyrylcholinesterase inhibitor... selectively inhibits BuChE to restore acetylcholine levels in the brain
Data Source
AI summary
The present invention discloses a selective butyrylcholinesterase inhibitor having a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and use thereof. The treatment efficacy of Alzheimer's disease, especially moderate to severe Alzheimer's disease, is tested through butyrylcholinesterase inhibitory activity, selectivity screening and toxicity to nerve cells as a carrier, and it is found that it has good target activity in vitro, extremely high selectivity and drug safety, can be used as a lead substance for further development of the treatment of Alzheimer's disease by selectively inhibiting butyrylcholinesterase.